Please login to the form below

Not currently logged in
Email:
Password:

Former Merck & Co exec to lead Seres

Roger Pomerantz was senior VP at pharma giant

Roger Pomerantz MerckSeres has appointed Dr Roger Pomerantz, formerly a senior figure at Merck & Co, to lead the company as CEO and chairman.

Dr Pomerantz was senior VP and worldwide head of licensing and acquisitions at Merck & Co, overseeing all licensing and acquisition activities at the company. This included external research and academic alliances.

He will now lead a company making advances in treat infectious diseases, with Seres' lead candidate a potential treatment for clostridium difficile (C. difficile).

Dr Pomerantz has considerable experience in the area of infectious diseases, serving as global franchise head of infectious diseases at Merck immediately prior to his role in licensing and acquisitions. 

Previously he was global head of infectious diseases for Johnson & Johnson having joined the company as president of its Tiobtec Pharmacueticals division, now known as Janssen Therapeutics.

In total Dr Pomerantz has been involved with the development of eight approved drugs for infectious diseases, covering HIV, hepatitis C and tuberculosis.

"With our lead product currently in clinical testing for the treatment of recurrent C. difficile, and a rapidly growing pipeline, Roger's expertise is ideally suited to provide the leadership that can execute on Seres' pioneering vision,” said Dr Noubar Afeyan, co-founder of Seres.

9th June 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics